The surgeons are not opening skulls—they're unclogging the exit route.
In a hospital outside Barcelona, surgeons are threading microscopic connections between lymphatic vessels and veins in the necks of Alzheimer's patients — not to cure the disease, but to ask whether the brain, given a cleaner drain, might slow its own unraveling. The trial, called ALCEA, is the first of its kind in Europe, and it rests on a relatively recent understanding that the brain possesses its own lymphatic waste system, one that may falter as dementia takes hold. Ten volunteers are participating in this Phase I study, which seeks first to establish safety, and only then to listen for any whisper of benefit. In a field where the disease outpaces every remedy, this quiet surgery in the neck represents a considered wager on the body's own capacity for self-repair.
- With 57 million people living with dementia worldwide and no cure in sight, the urgency to find new approaches has pushed medicine toward unconventional territory — including operating on the neck to treat the brain.
- The central tension is biological: toxic proteins like beta-amyloid and tau accumulate in Alzheimer's brains partly because the lymphatic drainage system in the neck becomes sluggish, and this trial bets that unblocking it could change the disease's course.
- Surgeons are borrowing a technique already proven in cancer care — cervical lymphaticovenous bypass — and redirecting it toward neurology, creating a microscopic shortcut that channels brain waste fluid into the bloodstream.
- One of the first two patients treated has shown early signs of functional improvement, a fragile signal the team is careful not to overinterpret while the 12-month follow-up continues.
- The trial is currently in its most cautious phase, prioritizing safety and feasibility over efficacy claims, with eight more surgeries still to come and months of biomarker and cognitive data yet to accumulate.
In an operating room at Hospital Germans Trias i Pujol in Badalona, Spain, surgeons are doing something Europe has never seen: operating on the necks of Alzheimer's patients to help their brains drain more effectively. No skulls are opened. Instead, using sutures so fine they require a surgical microscope, the team creates a tiny bridge between lymphatic vessels and veins in the neck. The clinical trial, called ALCEA, will follow ten carefully selected volunteers for at least a year.
The science draws on a discovery that reshaped how researchers understand the brain's internal housekeeping. Beyond blood flow, the brain relies on a network of lymphatic vessels in its surrounding membranes — vessels that carry waste products, including the toxic proteins beta-amyloid and tau, down through the neck toward the lymph nodes. When that drainage falters, the theory holds, Alzheimer's pathology may worsen. Improving it could give the brain a fighting chance to clear itself.
The technique — cervical lymphaticovenous bypass — is already established in treating lymphedema after cancer surgery. What is new is its application to neurological disease. A surgeon uses ultrasound to locate a lymph node and a small vein in the neck, then microsurgically connects them, redirecting lymphatic fluid into the bloodstream. The procedure is minimally invasive and typically requires only a brief hospital stay.
Participants were chosen for early-stage Alzheimer's, confirmed through amyloid scans, spinal fluid analysis, and cognitive testing — a window of opportunity made possible by modern diagnostics. One of the first two patients treated has shown what the team cautiously describes as preliminary signs of functional improvement, though conclusions remain far off.
This is a Phase I trial: safety and feasibility come first. With 57 million people living with dementia globally — a number projected to reach 139 million by 2050 — and no cure available, even a measured attempt to harness the brain's own waste-clearing system is worth following closely.
In a quiet operating room at Hospital Germans Trias i Pujol in Badalona, Spain, surgeons are attempting something that has never been tried in Europe: they are operating on the necks of Alzheimer's patients to clean their brains.
The procedure sounds counterintuitive. The surgeons are not opening skulls or touching brain tissue. Instead, they are creating a microscopic bridge in the neck—connecting lymphatic vessels to veins using sutures so fine they require a surgical microscope to place them. The goal is to give the brain a better way to drain its own waste. Two patients have already undergone the surgery. Eight more will follow as part of a clinical trial called ALCEA, which will track each participant for at least a year.
The science behind it rests on a discovery that upended how we understand the brain's housekeeping. For decades, researchers assumed the brain relied entirely on blood flow to clear away toxic proteins—particularly beta-amyloid and tau, the molecular hallmarks of Alzheimer's disease. But in recent years, scientists identified a network of lymphatic vessels in the membranes surrounding the brain, vessels that drain fluid and waste products through channels in the neck toward the lymph nodes. If those channels become congested or inefficient, the theory goes, toxic proteins accumulate. If they work better, the brain cleans itself more effectively.
This is a Phase I trial, which means the hospital's primary concern is not proving the surgery works—it is proving it is safe. The researchers will measure whether patients experience complications, whether the surgical connection remains functional, and whether any measurable changes appear in cognitive tests or biological markers of disease. One of the two patients already treated has shown what the team describes as "very preliminary" signs of functional improvement, though it is far too early to draw conclusions.
The technique itself is not new. Surgeons have used cervical lymphaticovenous bypass for years to treat lymphedema—the painful swelling that sometimes follows cancer surgery or radiation therapy. What is new is applying it to the brain. Dr. Carmen Higueras Suñé, who leads the plastic surgery team, explained the procedure: a surgeon uses ultrasound to locate a functioning lymph node and a small vein in the neck, then uses microsurgery to connect them, redirecting lymphatic fluid toward the bloodstream. The operation is minimally invasive, typically performed as outpatient surgery or with a brief hospital stay.
The patients in the trial are carefully selected. They have early-stage Alzheimer's disease, confirmed through strict biological criteria—amyloid scans, spinal fluid analysis, cognitive testing. They are at a stage where intervention might still matter, before neurodegeneration has advanced too far. Dr. Pau Pastor Muñoz, a neurologist at the hospital, noted that modern diagnostic tools now allow doctors to identify Alzheimer's disease years before symptoms become severe. That window of opportunity is what makes this trial possible.
The numbers underscore why this matters. The World Health Organization counted 57 million people with dementia in 2021, with Alzheimer's accounting for 60 to 70 percent of those cases. By 2050, that figure is projected to reach 139 million. There is no cure. Current medications offer modest slowing of decline. A surgical approach that enhances the brain's natural waste-clearing system, if it works, could reshape treatment entirely.
For now, the hospital is focused on the immediate task: completing the trial safely, documenting what happens to each patient's cognitive function and biomarkers, and determining whether the surgical connection holds up over time. The results will take months to accumulate. But in a field where options are limited and the disease burden is growing, even a carefully measured attempt to help the brain clean itself represents something worth watching.
Notable Quotes
This is a step forward to improve the symptoms of Alzheimer's, and it is a point of pride for Catalonia's health system that a Catalan hospital is leading this new therapeutic path in Spain and Europe.— Candela Calle, manager of the Barcelona Metropolitan North Health Region
We now have markers that allow us to diagnose the disease very early. That early diagnosis opens the door to intervening before neurodegeneration advances.— Dr. Pau Pastor Muñoz, neurologist
The Hearth Conversation Another angle on the story
Why operate on the neck when the problem is in the brain?
Because the brain doesn't clean itself in isolation. It has a drainage system—lymphatic vessels in the membranes around it—that channels waste toward the neck. If that drainage is sluggish, toxic proteins pile up. The surgeons aren't trying to fix the brain directly; they're trying to unclog the exit route.
And this technique already exists for other conditions?
Yes. It's been used for years in cancer patients who develop lymphedema—swelling caused by damaged lymph nodes. The surgery is proven safe in that context. What's novel here is asking whether improving brain drainage might slow cognitive decline.
Why is early-stage disease so important for this trial?
Because once neurons die, no amount of cleaning will bring them back. The window where intervention might matter is before the damage becomes irreversible. Modern diagnostics now let us catch Alzheimer's years before symptoms show up. That's the population they're targeting.
What does "very preliminary improvement" actually mean at this stage?
Honestly, it's too early to know. One of two patients showed some functional gains on cognitive testing. But this is Phase I—the focus is safety, not efficacy. They need to see if the surgery itself causes harm, if the connection stays open, if biomarkers shift. Everything else is just signal in the noise.
How long until we know if this actually works?
The trial runs for at least 12 months per patient, and they're enrolling sequentially. So we're looking at years before there's real data. This is a slow process by design. They're not trying to prove a miracle; they're trying to prove it's worth studying further.